title: Combination of intermittent calorie restriction and eicosapentaenoic acid for inhibition of mammary tumors.
abstract: There are a number of dietary interventions capable of inhibiting mammary tumorigenesis; however, the effectiveness of dietary combinations is largely unexplored. Here, we combined 2 interventions previously shown individually to inhibit mammary tumor development. The first was the use of the omega-3 fatty acid, eicosapentaenoic acid (EPA), and the second was the implementation of calorie restriction. MMTV-Her2/neu mice were used as a model for human breast cancers, which overexpress Her2/neu. Six groups of mice were enrolled. Half were fed a control (Con) diet with 10.1% fat calories from soy oil, whereas the other half consumed a diet with 72% fat calories from EPA. Within each diet, mice were further divided into ad libitum (AL), chronic calorie-restricted (CCR), or intermittent calorie-restricted (ICR) groups. Mammary tumor incidence was lowest in ICR-EPA (15%) and highest in AL-Con mice (87%), whereas AL-EPA, CCR-Con, CCR-EPA, and ICR-Con groups had mammary tumor incidence rates of 63%, 47%, 40%, and 59%, respectively. Survival was effected similarly by the interventions. Consumption of EPA dramatically reduced serum leptin (P < 0.02) and increased serum adiponectin in the AL-EPA mice compared with AL-Con mice (P < 0.001). Both CCR and ICR decreased serum leptin and insulin-like growth factor I (IGF-I) compared with AL mice but not compared with each other. These results illustrate that mammary tumor inhibition is significantly increased when ICR and EPA are combined as compared with either intervention alone. This response may be related to alterations in the balance of serum growth factors and adipokines.
authors.affiliation: University of Minnesota, Hormel Institute, 801 16th Ave. NE, Austin, MN 55912, USA.
authors.forename: Nancy K
authors.initials: NK
authors.lastname: Mizuno
authors.forename: Olga P
authors.initials: OP
authors.lastname: Rogozina
authors.forename: Christine M
authors.initials: CM
authors.lastname: Seppanen
authors.forename: D Joshua
authors.initials: DJ
authors.lastname: Liao
authors.forename: Margot P
authors.initials: MP
authors.lastname: Cleary
authors.forename: Michael E
authors.initials: ME
authors.lastname: Grossmann
mesh_terms: D052242:Adiponectin / Q000097:blood; D000818:Animals; D031204:Caloric Restriction; D003131:Combined Modality Therapy; D004032:Diet; D015118:Eicosapentaenoic Acid / Q000494:pharmacology*; D002149:Energy Intake; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D020738:Leptin / Q000097:blood; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000401:mortality / Q000517:prevention & control*; D008324:Mammary Tumor Virus, Mouse / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D015996:Survival Rate
chemical_list: D052242:Adiponectin; D015118:Eicosapentaenoic Acid; D007334:Insulin-Like Growth Factor I; D020738:Leptin; D018719:Erb-b2 Receptor Tyrosine Kinases
references.citation: Biochem Biophys Res Commun. 2002 Apr 26;293(1):622-8
references.pmid: 12054648
references.citation: J Nutr. 1993 Nov;123(11):1939-51
references.pmid: 8229312
references.citation: Cancer Metastasis Rev. 2010 Dec;29(4):641-53
references.pmid: 20821253
references.citation: J Nutr. 2005 May;135(5):983-8
references.pmid: 15867269
references.citation: Am J Clin Nutr. 1975 Sep;28(9):958-66
references.pmid: 1163480
references.citation: Am J Epidemiol. 1998 Feb 15;147(4):342-52
references.pmid: 9508101
references.citation: J Am Coll Surg. 2009 Jun;208(6):1093-8
references.pmid: 19476897
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5699-704
references.pmid: 14654554
references.citation: J Natl Cancer Inst. 1973 Nov;51(5):1479-83
references.pmid: 4762931
references.citation: J Natl Cancer Inst. 1993 Nov 3;85(21):1743-7
references.pmid: 8411258
references.citation: Environ Health Perspect. 1999 Apr;107(4):A182-3
references.pmid: 10383244
references.citation: J Natl Cancer Inst. 2006 Apr 5;98(7):436-8
references.pmid: 16595777
references.citation: Exp Biol Med (Maywood). 2007 Jan;232(1):70-80
references.pmid: 17202587
references.citation: JAMA. 2004 Mar 10;291(10):1226-30
references.pmid: 15010444
references.citation: Proc Nutr Soc. 2012 May;71(2):263-75
references.pmid: 22414375
references.citation: N Engl J Med. 2012 Jan 12;366(2):176-8
references.pmid: 22149874
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):836-43
references.pmid: 12223427
references.citation: Endocr Relat Cancer. 2007 Jun;14(2):189-206
references.pmid: 17639037
references.citation: Recent Results Cancer Res. 2009;181:97-111
references.pmid: 19213562
references.citation: Am J Physiol Regul Integr Comp Physiol. 2005 Aug;289(2):R486-R494
references.pmid: 16014450
references.citation: Endocrinol Metab Clin North Am. 2012 Jun;41(2):335-50, vi
references.pmid: 22682634
references.citation: Exp Biol Med (Maywood). 2004 Feb;229(2):182-93
references.pmid: 14734797
references.citation: Int J Cancer. 2003 Sep 20;106(5):766-70
references.pmid: 12866038
references.citation: J Clin Endocrinol Metab. 1998 Jan;83(1):214-8
references.pmid: 9435444
references.citation: Breast Cancer Res Treat. 2003 Feb;77(3):205-15
references.pmid: 12602920
references.citation: Breast Cancer Res Treat. 1999 May;55(2):149-60
references.pmid: 10481942
references.citation: Recent Pat Anticancer Drug Discov. 2011 May;6(2):166-77
references.pmid: 21247403
references.citation: Clin Cancer Res. 2006 Mar 1;12(5):1447-53
references.pmid: 16533767
references.citation: Nat Rev Cancer. 2004 Jul;4(7):519-27
references.pmid: 15229477
references.citation: Cold Spring Harb Perspect Biol. 2011 Feb 01;3(2):
references.pmid: 21047916
references.citation: Diabetes Care. 2003 Aug;26(8):2383-8
references.pmid: 12882866
references.citation: Nat Med. 1995 Dec;1(12):1311-4
references.pmid: 7489415
references.citation: Cancer Invest. 2010 Dec;28(10):1070-7
references.pmid: 20932221
references.citation: Curr Drug Targets. 2010 Sep;11(9):1121-32
references.pmid: 20545608
references.citation: Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32
references.pmid: 22124364
references.citation: Adv Food Nutr Res. 2012;65:211-22
references.pmid: 22361189
references.citation: Cancer Lett. 2006 Jun 8;237(1):109-14
references.pmid: 16019138
references.citation: Mol Cell Biol. 1992 Mar;12(3):954-61
references.pmid: 1312220
references.citation: Int J Cancer. 2006 Mar 15;118(6):1414-9
references.pmid: 16206269
references.citation: Int J Obes (Lond). 2011 May;35(5):714-27
references.pmid: 20921964
references.citation: J Clin Oncol. 2012 Jan 10;30(2):151-7
references.pmid: 22162577
references.citation: N Engl J Med. 1996 Feb 1;334(5):292-5
references.pmid: 8532024
references.citation: Breast Cancer Res Treat. 2005 Jul;92(2):187-95
references.pmid: 15986129